FDA clears OMNI Ultra device

- The FDA granted 510(k) clearance to Sight Sciences’ OMNI Ultra Surgical System, an implant‑free handheld device for minimally invasive glaucoma surgery. - The company says the device addresses all three known areas of outflow resistance through a single corneal microincision and targets a U.S. commercial launch in Q4 2026. - Sight Sciences expects to commercialize the handheld OMNI Ultra later this year, offering hospitals a non‑implant option that may change glaucoma workflow adoption. (mpo-mag.com) (biospace.com)

A new FDA 510(k) clearance gives Sight Sciences another implant-free glaucoma device to sell into the U.S. surgical market, this time with a design the company says is built around a simpler handheld workflow. Sight Sciences said on August 4 that the agency cleared the OMNI Ultra Surgical System for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adults with primary open-angle glaucoma. (sightsciences.com) The immediate point is not that this creates a brand-new glaucoma procedure. It is that Sight Sciences is trying to update how an existing minimally invasive glaucoma surgery, or MIGS, tool is delivered in the operating room. The company said OMNI Ultra is a handheld, implant-free system intended to treat all three known areas of aqueous outflow resistance through a single corneal microincision. (sightsciences.com) Why that matters: many MIGS products are tied to implants, while OMNI Ultra is positioned as a non-implant alternative. Sight Sciences said the device is the first FDA-cleared MIGS device for single-pass canaloplasty with its TruSync Plus feature, and said the system is designed to support canaloplasty first and then trabeculotomy in the same procedure. (sightsciences.com) The FDA record confirms the clearance route. The agency’s 510(k) database shows a cleared OMNI Surgical System submission for Sight Sciences, and FDA says a 510(k) is a premarket notification used to show a device is substantially equivalent to a legally marketed device rather than a full premarket approval process. (accessdata.fda.gov) That distinction matters for reading the announcement. A 510(k) clearance means the device can be marketed based on substantial equivalence under FDA’s device framework; it is not the same thing as the FDA declaring the product categorically superior to other glaucoma devices. The company’s claims about workflow, surgeon adoption or broader market impact are company statements, not findings attributed to the FDA. (accessdata.fda.gov) Sight Sciences framed the product around surgeon use and hospital adoption. In its release, the company said the handheld form factor may help expand procedural options for ophthalmic surgeons and stated that a U.S. commercial launch remains on track for the fourth quarter of 2026. (sightsciences.com) There is also a portfolio angle. Sight Sciences already markets OMNI-branded glaucoma systems, and company materials describe OMNI and OMNI Edge as implant-free MIGS technologies indicated in the United States to reduce intraocular pressure in adults with primary open-angle glaucoma. OMNI Ultra appears to extend that franchise with a new delivery format rather than opening a separate therapeutic category. (investors.sightsciences.com) So the story to watch from here is commercial execution, not another regulatory decision in the immediate term. Sight Sciences has said it expects a U.S. launch in Q4 2026, which means the next concrete markers are surgeon rollout, hospital uptake and any future company disclosures on adoption or revenue contribution. (sightsciences.com)

Get your own daily briefing

Scout delivers personalized news, insights, and conversations tailored to your role and industry.

Download on the App Store

Shared from Scout - Be the smartest in the room.